Stoke Therapeutics (STOK) Cash & Equivalents (2022 - 2025)
Historic Cash & Equivalents for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $83.4 million.
- Stoke Therapeutics' Cash & Equivalents fell 4440.99% to $83.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.4 million, marking a year-over-year decrease of 4440.99%. This contributed to the annual value of $128.0 million for FY2024, which is 3314.79% down from last year.
- Stoke Therapeutics' Cash & Equivalents amounted to $83.4 million in Q3 2025, which was down 4440.99% from $101.5 million recorded in Q2 2025.
- Stoke Therapeutics' 5-year Cash & Equivalents high stood at $274.8 million for Q1 2025, and its period low was $67.8 million during Q2 2022.
- Its 4-year average for Cash & Equivalents is $150.2 million, with a median of $150.0 million in 2024.
- As far as peak fluctuations go, Stoke Therapeutics' Cash & Equivalents surged by 18346.67% in 2023, and later crashed by 4755.32% in 2025.
- Stoke Therapeutics' Cash & Equivalents (Quarter) stood at $113.6 million in 2022, then surged by 68.59% to $191.4 million in 2023, then crashed by 33.15% to $128.0 million in 2024, then crashed by 34.84% to $83.4 million in 2025.
- Its last three reported values are $83.4 million in Q3 2025, $101.5 million for Q2 2025, and $274.8 million during Q1 2025.